{"nct_id":"NCT05523323","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","status_verified_date":"2025-04","start_date":"2020-10-30","start_date_type":"ACTUAL","primary_completion_date":"2023-08-25","primary_completion_date_type":"ACTUAL","completion_date":"2025-03-28","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}